When attention-deficit/hyperactivity disorder co-occurs with anxiety disorders: Effects on treatment

Expert Review of Neurotherapeutics

Volumn 7, Issue 8, 2007, Pages 981-988

  Manassis, Katharina ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Anxiety disorder; Attention deficit hyperactivity disorder; Child psychiatry; Comorbidity; Psychopharmacology; Psychotherapy

Indexed keywords

ANTIDEPRESSANT AGENT; ATOMOXETINE; CENTRAL STIMULANT AGENT; FLUOXETINE; FLUVOXAMINE; METHYLPHENIDATE; SEROTONIN UPTAKE INHIBITOR;

ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BEHAVIOR MODIFICATION; CHILD DEVELOPMENT; CLINICAL TRIAL; COGNITION; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DEVELOPMENTAL STAGE; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; EVIDENCE BASED MEDICINE; FAMILY STUDY; HUMAN; INFORMATION PROCESSING; MONOTHERAPY; NEUROPSYCHIATRY; PATHOGENESIS; PREVALENCE; PROGNOSIS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT RESPONSE;

ANXIETY DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; HUMANS; TREATMENT OUTCOME;

EID: 34548038385     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.8.981     Document Type: Review

References (54)

1. Newcorn JH, Miller SR, Ivanova I et al. Adolescent outcome of ADHD: impact of childhood conduct and anxiety disorders. CNS Spectr. 9, 668-678 (2004).
2. Pliszka SR, Carlson C, Swanson JM. Anxiety disorders. In: ADHD with Comorbid Disorders: Clinical Assessment and Management. Guilford, NY, USA 165-185 (1999).
3. Tannock R. Attention deficit disorders with anxiety disorders. In: Subtypes of Attention Disorders in Children, Adolescents, and Adults. Brown TE (Ed.). American Psychiatric Press, DC, USA (2000).
4. Jensen PS, Martin D, Cantwell DP. Comorbidity in ADHD: implications for research, practice, and DSM-V. J. Am. Acad. Child. Adolesc. Psychiatry 36, 1065-1079 (1997).
5. Souza I, Pinheiro MA, Mattos P. Anxiety disorders in an attention-deficit/hyperactivity disorder clinical sample. Arq. Neuropsiquiatr. 63, 407-409 (2005).
6. Busch B, Biederman J, Cohen LG, Sayer JM, Monuteaux MC, Mick E. Correlates of ADHD among children in pediatric and psychiatric clinics. Psychiatric Services 53, 1102-1111 (2002).
7. Safren SA. Prevalence of childhood ADHD among patients with generalized anxiety disorder and a comparison condition, social phobia. Depress. Anxiety 13, 190-191 (2001).
8. Vance A, Costin J, Barnett R, Luk E, Maruff P, Tonge B. Characteristics of parent- and child-reported anxiety in psychostimulant medication naive clinically referred children with attention deficit hyperactivity disorder, combined type (ADHD-CT). Aust. NZ J. Psychiatry 36, 234-239 (2002).
9. Pliszka SR. Comorbidity of attention-deficit hyperactivity disorder and overanxious disorder. J. Am. Acad. Child. Adolesc. Psychiatry 31, 197-203 (1992).
10. Power TJ, Costigan TE, Eiraldi RB, Leff SS. Variations in anxiety and depression as a function of ADHD subtype by DSM-IV: do subtype differences exist or not? J. Abnorm. Child. Psychol. 32, 27-37(2004).
11. Manassis K, Tannock R, Young A, Francis-John S. Cognition in anxious children with attention deficit hyperactivity disorder: a comparison with clinical and normal children. Behav. Brain Funct. 3, 4 (2007). • One of the few studies of cognition in anxiety disorders (ANX) plus attention-deficit/hyperactivity disorder (ADHD) to include an ANX only comparison group as well as children with ADHD only. This will be important in future studies of this comorbidity if we are to understand it as more than merely a subset of children with ADHD.
12. MTA Cooperative Group. Moderators and mediators of treatment response for children with ADHD. Arch. Gen. Psychiatry 56, 1088-1096 (1999).
13. Brown TE. ADHD with anxiety disorders. In: Attention-Deficit Disorders and Comorbidities in Children, Adolescents, and Adults. American Psychiatric Press, DC, USA 80-105 (2000).
14. Jensen PS, Hinshaw SP, Kraemer HC, Lenora N, Newcorn JH, Abikoff HB. ADHD comorbidity findings form the MTA study: comparing comorbid subgroups. J. Am. Acad. Child. Adolesc. Psychiatry 40, 147-158 (2001).
15. Sanders M, Arduca Y, Karamitsios M, Boots M, Vance A. Characteristics of anxiety disorders in medication naive, clinically referred children with attention deficit hyperactivity disorder, combined type (ADHD-CT) and dysthymic disorder (DD). Aust. NZ J. Psychiatry 39, 359-365 (2005).
16. Vance A. Stimulant medication response in ADHD and comorbid anxiety disorder. In: Handbook of ADHD. Bellgrove M, Fitzgerald M, Gill M (Eds). Wiley, IN, USA 331-334 (2007).
17. Levy F. Synaptic gating and ADHD: a biological theory of comorbidity of ADHD and anxiety. Neuropsychopharm. 29, 1589-1596 (2004).
18. Manassis K, Tannock R, Barbosa J. Dichotic listening and response inhibition in children with comorbid anxiety disorders and ADHD. J. Am. Acad. Child. Adolesc. Psychiatry 39, 1152-1159 (2000).
19. Perrin S, Last CG. Relationship between ADHD and anxiety in boys: results from a family study. J. Am. Acad. Child. Adolesc. Psychiatry 35, 988-996 (1996).
20. Braaten EB, Biederman J, Monuteaux MC et al. Revisiting the association between attention-deficit/hyperactivity and anxiety disorders: a family risk analysis. Biol. Psychiatry 53, 93-99 (2003).
21. Pfiffner LJ, McBurnitt K. Family correlates of comorbid anxiety disorders in children with attention deficit/hyperactivity disorder. J. Abnorm. Child. Psychol. 34, 725-735 (2006).
22. Pliszka SR, Maas JW, Javors MA, Rogeness GA, Baker J. Urinary catecholamines in attention-deficit hyperactivity disorder with and without comorbid anxiety. J. Am. Acad. Child. Adolesc. Psychiatry 33, 1165-1173 (1994).
23. Vance AL, Luk ES. Attention deficit hyperactivity disorder and anxiety: is there an association with neurodevelopmental deficits? Aust. NZ J. Psychiatry 32, 650-657 (1998).
24. Vance A. ADHD, combined type in primary school age children: investigations of its association with oppositional defiant, dysthymic and anxiety disorders. In: Attention Deficit Hyperactivity Disorder (ADHD) Research. Larimer MP (Ed.). Nova Press, NY, USA 59-94 (2005).
25. Schatz DB, Rostain AL. ADHD with comorbid anxiety: a review of the current literature. J. Attention Dis. 10, 141-149 (2006). •• Excellent review of the complexities involved in understanding cognition in ANX + ADHD. The paper reviews recent literature and various cognitive hypotheses needing further study in this population.
26. Vasey MW, Dagleish T, Silverman WK. Research on information-processing factors in child and adolescent psychopathology: a critical commentary. J. Clin. Child. Adolesc. Psychol. 32, 81-93 (2003).
27. Oosterlaan J. Response inhibition and response re-engagement in attention deficit/hyperactivity disorder, disruptive, anxious, and normal children. Behav. Brain Res. 94, 33-43 (1998).
28. Oosterlaan J, Seargeant JA. Response inhibition in AD/HD, CD, comorbid AD/HD and CD, anxious, and control children: a meta-analysis of studies with the stop task. J. Child Psychol. Psychiatry 39, 411-425 (1998).
29. Korenblum CB, Chen SX, Manassis K, Schachar RJ. Performance monitoring and response inhibition in anxiety with and without comorbid ADHD. Depress. Anxiety 24(4), 227-232 (2007).
30. Eslinger PJ. Conceptualizing, describing, and measuring components of executive function: a summary. In: Attention, Memory, and Executive Function. Lyon GR, Krasnegor NA (Eds). Paul H Brookes Publishing, MD, USA (1996).
31. Pliszka SR. Effect of anxiety on cognition, behavior, and stimulant response in ADHD. J. Am. Acad. Child. Adolesc. Psychiatry 28, 882-887 (1989).
32. Tannock R, Ickowicz A, Schachar R. Differential effects of methylphenidate on working memory in ADHD children with and without anxiety. J. Am. Acad. Child. Adolesc. Psychiatry 34, 886-896 (1995). • One of the few studies to examine the effects of stimulant medication on higher order cognitive functions in ADHD, and the only one to date to do so in relation to anxious comorbidity.
33. Eysenck MW, Calvo MG. Anxiety and performance: the processing efficiency theory. Cogn. Emot. 6, 409-434 (1992).
34. Martinussen R, Hayden J, Hogg-Johnson S, Tannock R. A meta-analysis of working memory impairments in children with attention-deficit/hyperactivity disorder. J. Am. Acad. Child. Adolesc. Psychiatry 44, 377-384 (2005).
35. Carlson CL, Mann M. Sluggish cognitive tempo predicts a different pattern of impairment in attention deficit/hyperactivity disorder, predominantly inattentive type. J. Clin. Child. Adolesc. Psychol. 31, 123-129 (2002).
36. Hartmann CA, Willcutt WG, Rhee SH, Pennington BF. The relationship between sluggish cognitive tempo and DSM IV ADHD. J. Abnorm. Child. Psychol. 35, 491-503 (2004).
37. March JS, Swanson JM, Arnold EL, Hoza B, Conners CK, Hinshaw SP. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). J. Abnorm. Child. Psychol. 28, 527-541 (2000). •• Sophisticated analysis of anxiety disorders in relation to treatment outcome in the multimodal treatment study of children with ADHD, including a clear description of limitations of the methods used.
38. Diamond IR, Tannock R, Schachar RJ. Response to methylphenidate in children with ADHD and comorbid anxiety. J. Am. Acad. Child. Adolesc. Psychiatry 38, 402-409 (1999).
39. Walkup JT, Labellarte MJ, Riddle MA et al. Searching for moderators and mediators of pharmacological treatment in children and adolescents with anxiety disorders. J. Am. Acad. Child. Adolesc. Psychiatry 42, 13-21 (2003).
40. Abikoff H, McGough J, Vitiello B et al. Sequential pharmacotherapy for children with comorbid attention-deficit hyperactivity and anxiety disorders. J. Am. Acad. Child. Adolesc. Psychiatry 44, 418-427 (2005). • Cleverly designed study that sought to determine if fluvoxamine adds any benefit above and beyond that conferred by stimulants in ANX + ADHD.
41. Mohammadi MR, Akhondzadeh S. Pharmacotherapy of attention-deficit/ hyperactivity disorder: nonstimulant medication approaches. Expert Rev. Neurother. 7, 195-201 (2007). • By thoroughly reviewing the literature, these authors are able to draw appropriately cautious conclusions about nonstimulant treatment in ADHD, despite its recent popularity.
42. Prasad S, Harpin V, Poole L et al. A multi-centre randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder. Curr. Med. Res. Opin. 23, 379-394 (2007).
43. Perwien AR, Kratochvil CJ, Faries DE et al. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder: what are the long-term health-related quality of life outcomes? J. Child. Adolesc. Psychopharmacol. 16, 713-724 (2006).
44. Troost PW, Steenhuis MP, Tuynman-Qua HG et al. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J. Child. Adolesc. Psychopharmacol. 16, 611-619 (2006).
45. Kratchovill CJ, Newcorn JH, Arnold LE et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J. Am. Acad. Child. Adolesc. Psychiatry 44, 915-924 (2005).
46. Kendall PC, Flannery-Schroeder E, Panichelli-Mindel SM, Southam-Gerow M, Heni M. Therapy for youths with anxiety disorders: a second randomized clinical trial. J. Consult. Clin. Psychol. 65, 366-380 (1997).
47. Manassis K, Mendlowitz SL, Scapillato D et al. Group and individual cognitive-behavioral therapy for childhood anxiety disorders: a randomized trial. J. Am. Acad. Child. Adolesc. Psychiatry 41, 1423-1430 (2002).
48. Southam-Gerow MA, Kendall PC, Weersing VR. Examining outcome variability: correlates of treatment response in an adolescent anxiety clinic. J. Clin. Child. Psychol. 30, 422-436 (2001).
49. Manassis K. Keys to Parenting Your Anxious Child. Barron's Educational, NY, USA (1996).
50. Steele M, Jensen PS, Quinn DM. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin. Ther. 28, 1892-1908 (2006).
51. Cobham VE, Dadds MR, Spence SH. The role of parental anxiety in the treatment of childhood anxiety. J. Consult. Clin. Psychol. 66, 893-905 (1998).
52. Manassis K, Monga S. A therapeutic approach to children and adolescents with anxiety disorders and associated comorbid conditions. J. Am. Acad. Child. Adolesc. Psychiatry 40, 115-117 (2001).
53. McClure EB, Monk CS, Nelson EE et al. Abnormal attention modulation of fear circuit functioning in pediatric generaliezd anxiety disorder. Arch. Gen. Psychiatry 64, 97-106 (2007).
54. Chorpita BF. Modular Cognitive Behavioral Therapy for Childhood Anxiety Disorders. Guilford, NY, USA (2007).